Selecting MM Therapy in Patients With Comorbidities
Agenda
Program Goals and Disclosure
Managing the Patient With Diabetes and MM
Diabetes and MM
Corticosteroids
Peripheral Neuropathy in Multiple Myeloma
Diabetic Autonomic Neuropathy
Managing Peripheral Neuropathy
Key Takeaways
MM Therapeutic Agents Associated AEs
Treating Patients With Renal Impairment
Renal Impairment in MM
Management
Dose Modifications With Renal Impairment
Key Takeaways
Treating Patients With a History of Thromboembolism
Risk of Thromboembolism in MM
VTE Incidence With Immunomodulatory Agents
Prophylaxis
Management
Treating Patients With a History of Cardiac Disease
Background
ASPIRE KRd vs Rd
ENDEAVOR Carfilzomib/Dex vs Bortezomib/Dex
Carfilzomib in Patients With Cardiac History
Other MM Agents and Cardiotoxicity
Balancing Efficacy and Convenience for the Frail Patient
MM Patients Are Heterogeneous
IMWG Geriatric Assessment
IMWG Frailty Score ADL and IADL Components
FIRST Trial Continuous Rd vs Rd-18 vs MPT
UPFRONT VD vs VTP vs VMP
Key Takeaways
Optimizing Adherence for Patients With Comorbidities
Components of Adherence
Patient and Caregiver Education
Impact of Comorbidities
Abbreviations
Abbreviations
Abbreviations